Tuberous Sclerosis Complex (TSC) is a genetic disorder characterized by the growth of numerous non-cancerous (benign) tumors in many parts of the body. These tumors can occur in the skin, brain, kidneys, and other organs, in some cases leading to significant health problems. It was firstly described in the 1880s by French neurologist Désiré-Magloire Bourneville.
TSC is a neurocutaneous disorder that is caused by mutations in one of the two different genes called TSC1 and TSC2. These two genes lead to a protein product, called hamartin and tuberin. Both of these are involved in a complicated schema of normal cell signalling pathways. Any mutation in either of the TSC gene disrupts the main pathways, resulting in further alteration in cellular differentiation, growth, and proliferation. TSC alters the cellular proliferation and differentiation, resulting in hamartomas of various organs, tumour formation, and altered neuronal migration.
Tuberous Sclerosis Complex is a highly variable disorder which is characterized by the abnormalities of the skin, central nervous system tumors, renal disorders, neuropsychiatric disorders, Eye abnormalities, pulmonary disorders and delay in Development. Its signs and symptoms differ from person to a person. Males and females are affected in equal numbers and the disorder occurs in all races and ethnic groups.
DelveInsight’s “Tuberous Sclerosis Complex Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Tuberous Sclerosis Complex , historical and forecasted epidemiology as well as the Tuberous Sclerosis Complex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Tuberous Sclerosis Complex market report provides current treatment practices, emerging drugs, Tuberous Sclerosis Complex market share of the individual therapies, current and forecasted Tuberous Sclerosis Complex market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Tuberous Sclerosis Complex treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Key Highlight of Tuberous Sclerosis Complex Market
As per National Institute Of Neurological Disorders and Stroke, Tuberous Sclerosis Complex affects as many as 25,000 to 40,000 individuals in the United States and about 1 to 2 million individuals worldwide, with an estimated prevalence of one in 6,000 newborns.
As per Tuberous Sclerosis Alliance, at least two children born each day have Tuberous Sclerosis Complex.
According to the National Organization of Rare Disorders, the prevalence in Europe is estimated to be approximately 1 in 25,000 to 1 in 11,300. As per the Graffigna et.al.2013, Tuberous Sclerosis Complex affects approximately 5000 individuals in Italy.
As per a study conducted by Cockerell et al., 2017, renal manifestations are present in 48%-85% of Tuberous Sclerosis Complex patients and include angiomyolipomas (AMLs), cysts, and, to a lesser degree, development of renal cancers or progression toward renal insufficiency in French patients.
Visit for sample pages:
The Tuberous Sclerosis Complex market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Tuberous Sclerosis Complex market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The market segment gives a thorough detail of Tuberous Sclerosis Complex market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The Tuberous Sclerosis Complex epidemiology division provides insights about historical and current Tuberous Sclerosis Complex patient pool and forecasted trends for every seven major countries.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The Tuberous Sclerosis Complex Epidemiology part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Drug chapter segment of the Tuberous Sclerosis Complex report encloses the detailed analysis of Tuberous Sclerosis Complex marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
It also helps to understand the Tuberous Sclerosis Complex clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Some of the key companies in Tuberous Sclerosis Complex Market include:
Nobelpharma Co., Ltd
Takeda Pharmaceutical Company Limited
Increasing awareness, the introduction of novel drugs and changing lifestyle are some of the key factors driving the growth of the Tuberous Sclerosis Complex market globally.
Owing to the launch of upcoming therapies, the Tuberous Sclerosis Complex market size is expected to increase during the forecast period (2019-2030)
Table of contents
1. Key Insights
2. Executive Summary of Tuberous Sclerosis Complex
3. Competitive Intelligence Analysis for Tuberous Sclerosis Complex
4. Tuberous Sclerosis Complex : Market Overview at a Glance
5. Tuberous Sclerosis Complex : Disease Background and Overview
6. Tuberous Sclerosis Complex Patient Journey
7. Tuberous Sclerosis Complex Epidemiology and Patient Population
8. Tuberous Sclerosis Complex Treatment Algorithm, Current Treatment, and Medical Practices
9. Tuberous Sclerosis Complex Unmet Needs
10. Key Endpoints of Tuberous Sclerosis Complex Treatment
11. Tuberous Sclerosis Complex Marketed Products
12. Tuberous Sclerosis Complex Emerging Therapies
13. Tuberous Sclerosis Complex : Seven Major Market Analysis
14. Attribute analysis
15. Market Outlook of Tuberous Sclerosis Complex
16. Access and Reimbursement Overview of Tuberous Sclerosis Complex
17. KOL Views on Tuberous Sclerosis Complex market
18. Tuberous Sclerosis Complex Market Drivers
19. Tuberous Sclerosis Complex Market Barriers
20.2. Report Methodology
21. DelveInsight Capabilities
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States